The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
Open accessAbstract
Purpose: Hepatocellular carcinoma (HCC) incidence rates have been increasing in the United States for the past 35 years. Because HCC has a poor prognosis, quantitative forecasts could help to inform prevention and treatment strategies to reduce the incidence and burden of HCC. Methods: Single-year HCC incident case and population data for the years 2000 to 2012 and ages 35 to 84 years were obtained from the SEER 18 Registry Database. We forecast incident HCC cases through 2030, using novel age-period-cohort models and stratifying by sex, race/ethnicity, and age. Rates are presented because absolute numbers may be influenced by population increases. Results: Rates of HCC increased with each successive birth cohort through 1959. However, rates began to decrease with the 1960 to 1969 birth cohorts. Asians/Pacific Islanders (APIs) have had the highest HCC rates in the United States for many years, but the rates have stabilized and begun to decline in recent years. Between 2013 and 2030, rates among APIs are forecast to decline further, with estimated annual percentage changes of −1.59% among men and −2.20% among women. Thus, by 2030, Asians are forecast to have the lowest incidence rates among men, and Hispanics are forecast to have the highest rates among men (age-standardized rate, 44.2). Blacks are forecast to have the highest rate among women (age-standardized rate, 12.82). Conclusion: Although liver cancer has long had some of the most rapidly increasing incidence rates, the decreasing rates seen among APIs, individuals younger than 65 years, and cohorts born after 1960 suggest that there will be declines in incidence of HCC in future years. Prevention efforts should be focused on individuals in the 1950 to 1959 birth cohorts, Hispanics, and blacks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Permutation tests for joinpoint regression with applications to cancer rates
Kim, H.-J., Fay, M. P., Feuer, E. J., & Midthune, D. N. (2000) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z · Cited by 6,318
International Classification of Diseases for Oncology
National Cancer Institute (2020) · Definitions · doi:10.32388/1bjeus · Cited by 3,805
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
El-Serag, H. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.061 · Cited by 3,380
Schweitzer, A., Horn, J., Mikolajczyk, R. T., Krause, G., & Ott, J. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61412-x · Cited by 2,742
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S. C., Schultz, M., Davis, M. N., Kayali, Z., Reddy, K. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214853 · Cited by 1,788
Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
Smith, B. D., Smith, G. L., Hurria, A., Hortobagyi, G. N., & Buchholz, T. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8983 · Cited by 1,721
Altekruse, S. F., McGlynn, K. A., & Reichman, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7753 · Cited by 1,694
Self-citationObesity and Severe Obesity Forecasts Through 2030
Finkelstein, E. A., Khavjou, O. A., Thompson, H., Trogdon, J. G., Pan, L., Sherry, B., & Dietz, W. (2012) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2011.10.026 · Cited by 1,418
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Afdhal, N., Reddy, K. R., Nelson, D. R., Lawitz, E., Gordon, S. C., Schiff, E., Nahass, R., Ghalib, R., Gitlin, N., Herring, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316366 · Cited by 1,307
Cited by
Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,539
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
AASLD guidelines for the treatment of hepatocellular carcinoma
Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A. (2018) · Hepatology · doi:10.1002/hep.29086 · Cited by 4,070
Epidemiology of Hepatocellular Carcinoma
McGlynn, K. A., Petrick, J. L., & El‐Serag, H. B. (2021) · Hepatology · doi:10.1002/hep.31288 · Cited by 2,147
Self-citationHepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Vogel, A., Cervantes, A., Chau, I., Daniele, B., Llovet, J. M., Meyer, T., Nault, J. C., Neumann, U., Ricke, J., Sangro, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy308 · Cited by 1,048
Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence
Kerr, J., Anderson, C., & Lippman, S. M. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30411-4 · Cited by 677
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Fujiwara, N., Friedman, S. L., Goossens, N., & Hoshida, Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.016 · Cited by 659
Raoul, J.-L., Forner, A., Bolondi, L., Cheung, T. T., Kloeckner, R., & de Baere, T. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.11.002 · Cited by 643
Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Massarweh, N. N., & El-Serag, H. B. (2017) · Cancer Control · doi:10.1177/1073274817729245 · Cited by 634
Noureddin, M., Vipani, A., Bresee, C., Todo, T., Kim, I. K., Alkhouri, N., Setiawan, V. W., Tran, T., Ayoub, W. S., Lu, S. C., et al. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0088-6 · Cited by 578
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
Gordan, J. D., Kennedy, E. B., Abou-Alfa, G. K., Beg, M. S., Brower, S. T., Gade, T. P., Goff, L., Gupta, S., Guy, J., Harris, W. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02672 · Cited by 570
Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics
Islami, F., Ward, E. M., Sung, H., Cronin, K. A., Tangka, F. K. L., Sherman, R. L., Zhao, J., Anderson, R. N., Henley, S. J., Yabroff, K. R., et al. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab131 · Cited by 478
Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012
White, D. L., Thrift, A. P., Kanwal, F., Davila, J., & El-Serag, H. B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.020 · Cited by 418
van der Pol, C. B., Lim, C. S., Sirlin, C. B., McGrath, T. A., Salameh, J.-P., Bashir, M. R., Tang, A., Singal, A. G., Costa, A. F., Fowler, K., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.11.020 · Cited by 334
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
Gordan, J. D., Kennedy, E. B., Abou-Alfa, G. K., Beal, E., Finn, R. S., Gade, T. P., Goff, L., Gupta, S., Guy, J., Hoang, H. T., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02745 · Cited by 312
Metadata
- Authors
- Petrick, J. L., Kelly, S. P., Altekruse, S. F., McGlynn, K. A., & Rosenberg, P. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-05-20
- Volume
- 34
- Issue
- 15
- Pages
- 1787-1794
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2341369626
- Cited by
- 442
- References
- 33
- FWCI
- 24.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.